Skip to main content

Advertisement

Table 2 Comparison of baseline characteristics between synchronous (N = 144) and metachronous (N = 70) mRCC groups

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

   Synchronous Metachronous P-value
(N = 144) (N = 70)
Age (years, min-max)   59.0 (26.0–81.0) 56.0 (33.0–76.0) 0.232a
Gender Male 118 (81.9) 48 (68.6) 0.028b
Female 26 (18.1) 22 (31.4)  
Nephrectomy Yes 52 (36.6) 69 (100.0) <.001b
Treatment free interval ≥1 yr 8 (5.6) 48 (68.6) <.001c
<  1 yr 136 (94.4) 22 (31.4)  
Anemia   111 (77.1) 59 (84.3) 0.221b
Hypercalcemia   20 (14.4) 8 (11.6) 0.578b
Neutrophilia   21 (15.1) 12 (17.7) 0.639b
Elevated LDH >×1.5ULN 39 (38.2) 10 (23.3) 0.082b
KPS >  80 135 (97.1) 69 (100) 0.304c
≤ 80 4 (2.9) 0 (0)  
Thrombocytosis > 400 K 18 (12.5) 4 (5.7) 0.125b
First line therapy Immunotherapy 89 (61.8) 37 (52.9) 0.212b
Targeted therapy 55 (38.2) 33 (47.1)  
Heng risk Intermediate 107 (74.3) 64 (91.4) 0.003b
Poor 37 (25.7) 6 (8.6)  
Tumor (T) T1 - T2 70 (67.3) 26 (49.1) 0.027b
T3 -T4 34 (32.7) 27 (50.9)  
Lymph node(N) N0 49 (47.1) 5 (20.0) <.001b
N1 25 (24.0) 20 (80.0)  
Nx 30 (28.9) 0 (0.0)  
Fuhrman nuclear grade G1-G2 30 (33) 11 (21.6) 0.151b
G3-G4 61 (67) 40 (78.4)  
Histology Clear cell 113 (96.6) 51 (86.4) 0.022c
Non-clear cell 4 (3.4) 8 (13.6)  
Treatment duration (Month) 3.4 (1.0–70.4) 5.3 (1.0–62.0) 0.058a
Follow-up duration (Month) 81.3 (4.8–141.5) 142.3 (9.4–147.6) 0.005d
Progression free survival (Month, median(95%CI)) 4.4 (3.1–5.2) 5.9 (4.1–9.5) 0.044d
Cancer specific survival (Month, median(95%CI)) 9.6 (7.4–13.8) 21.3 (15.1–29.3) <.001d
  1. KPS Karnofsky performance status
  2. aWilcoxon rank sum test, bChi-square test, cFisher exact test, d: Log-rank test